Hospital ventilators vs. home ventilation: where the line actually sits

The word 'ventilator' spans two genuinely different product worlds. On one side: ICU platforms — the $34,500–$55,000 machines in our institutional catalog — built for continuous invasive support of unstable patients, with redundant systems, comprehensive alarms, and the assumption of trained staff at arm's reach around the clock. On the other: home-care and portable life-support ventilators like ResMed's Astral 100 and 150 ($7,495 and $8,995), listed in our sleep and bi-level catalog, built for stable patients on established settings in unmonitored environments.

The engineering differences follow from the environments. Home ventilators prioritize simplicity, quiet, battery portability, and alarm schemes a family caregiver can act on; ICU platforms prioritize measurement depth, mode breadth, and integration with hospital monitoring and gas infrastructure. Neither is a compromised version of the other — an Astral in an ICU would be under-instrumented, and an Evita in a living room would be unusable.

The line between them is drawn by clinical stability, not disease severity: home ventilation serves patients whose settings are established and whose condition is predictable enough for the machine to run without a clinician present — which is why the transition out of the hospital is a careful, prescriber-led process involving training for everyone who'll touch the machine. Our bi-level and ventilation piece in the CPAP guide covers the adjacent consumer-facing territory.

For institutional buyers the distinction matters at the fleet edges: long-term acute care and skilled nursing sit between the poles, and the right platform there depends on staffing model more than diagnosis mix. That's a conversation worth having before the RFP is drafted — it's the most common place we see facilities specify a class of machine their staffing can't actually support.